Richard Hatchett

So the other four candidates, apart from Dr.

Mark Dibotis, Dr. Richard Hatchett, who we all know has led CEPI for so long.

He's leaving next year.

We've got Lutz Higgemann, President of Global Health at Novartis.

Ebola, we were I mean, we have Ebola vaccines we have.

We have our good friend Richard Hatchett at CEPI making a, you know, a Bundabujo vaccine, multiple Bundabujo vaccine products in less than 100 days.

You know, and CEPI's done great work.

CEPI said, I love what CEPI did in terms of an anchoring.

Have you seen anything on the human side of prediction from a public health perspective? And it sort of harps back to your debate Department of Defense, Department of War experience, because that was a really important question for an operational unit.

And in those cases, you actually had, I mean, part of the ability in the real world to understand this is, can you bring in somebody longitudinally to understand their environmental metagenomic change? to be able to predict who's more susceptible.

And, you know, you and I have had friends who have looked at this with the Marines in various ways, but on the human side of susceptibility and the diversity of humans to these pathogens, have you seen progress in being able to determine who might be susceptible to things like long COVID? Yeah.

work in